Avacta Group Plc (AIM: AVCT)
London flag London · Delayed Price · Currency is GBP · Price in GBX
49.60
+3.10 (6.66%)
Nov 22, 2024, 11:07 AM GMT+1

Avacta Group Company Description

Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally.

The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets.

The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells.

It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPα.

The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics.

Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Avacta Group Plc
Country United Kingdom
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 154
CEO Christina Coughlin

Contact Details

Address:
Thorp Arch Estate
Wetherby, LS23 7FA
United Kingdom
Phone 44 1904 217 070
Website avacta.com

Stock Details

Ticker Symbol AVCT
Exchange London Stock Exchange AIM
Fiscal Year January - December
Reporting Currency GBP
ISIN Number GB00BYYW9G87
SIC Code 8731

Key Executives

Name Position
Christina Coughlin Chief Executive Officer
Tony Gardiner Chief Financial Officer